<DOC>
	<DOCNO>NCT02153320</DOCNO>
	<brief_summary>The purpose long-term follow-up study evaluate persistence cellular humoral immune response 4 year first dose GSK Biologicals ' investigational vaccine formulation contain HBsAg ( use model antigen ) adjuvant .</brief_summary>
	<brief_title>Study Evaluate Persistence Cellular Humoral Immune Response Following Vaccinations With GlaxoSmithKline ( GSK ) Biologicals ' Candidate Vaccines Containing HBsAg Different Adjuvants Healthy Adult Volunteers</brief_title>
	<detailed_description>Subjects long-term follow-up study recruit among subject complete study 287615 ( NCT00508833 ) enrol specific group . All subject vaccinate study 287615 ( NCT00508833 ) accord 0 , 1 , 10 month schedule . No new subject enrol vaccine administer long-term follow-up study . There single visit Year 4 blood sample immunogenicity assay take .</detailed_description>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe comply requirement protocol . Subjects take part complete study 287615 ( NCT00508833 ) . Written inform consent obtain subject . Healthy subject establish medical history enter study . Use investigational nonregistered product study vaccine ( ) within 30 day precede blood sampling , plan use study period . Chronic administration immunosuppressant immunemodifying drug within three month prior blood sampling . Administration immunoglobulin within three month precede blood sampling plan administration study period . Pregnant lactate female . Documented HIVpositive subject .</criteria>
	<gender>All</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>HBsAg</keyword>
	<keyword>Persistence immune response</keyword>
	<keyword>Adjuvants</keyword>
</DOC>